8/11/2019 Principi Tp Antibiotica 2014
1/291
Principi di Terapia Antibiotica
Corso integrato di Terapia Medica
18 Marzo 2014
8/11/2019 Principi Tp Antibiotica 2014
2/291
Considerazioni generali1. Tipo di infezione
agenti eziologici pi frequenti gravit
2. Particolarit del paziente Precedenti terapie antibiotiche Fattori di rischio x MDR (Pneumococco, MRSA, VRSA, P.
Aeruginosa, Enterococco, VRE) Presenza di allergie Condizioni particolari: insuff renale, diabete, disfagia
3. Particolarit locali Pattern di resistenza Disponibilit del farmaco, costi
8/11/2019 Principi Tp Antibiotica 2014
3/291
8/11/2019 Principi Tp Antibiotica 2014
4/291
8/11/2019 Principi Tp Antibiotica 2014
5/291
Considerazioni generali4. Antibiotico
Meccanismo dazione Attivit Spettro dazione
Effetti collaterali Resistenze (comuni o rare) Azione sinergica
Via di somministrazione
8/11/2019 Principi Tp Antibiotica 2014
6/291
Modalit della tp antibiotica
A. Terapia profilattica
B. Terapia empirica
C. Terapia specifica
8/11/2019 Principi Tp Antibiotica 2014
7/291
Terapia profilattica In alcune classi particolari di pazienti
HIV+: profilassi con Bactrim per Pneumocistosi Pz con bronchiectasie in fibrosi cistica
Dopo esposizione ad agente infettivo Meningite da Neisseria
Prima di una procedura chirurgica
Profilassi per endocardite Interventi chirurgici su tratto GE
8/11/2019 Principi Tp Antibiotica 2014
8/291
Terapia empirica Nelle infezioni gravi (ad es: polmonite, pielonefrite,
colecistite) dopo aver prelevato gli esami colturali ed inattesa degli esiti: entro 24 ore dalla diagnosi
in alcuni casi molto gravi e/o ad evoluzione fulminante(meningite, infezioni necrotizzanti dei tessuti molli, sepsigrave/shock settico, neutropenia febbrile, sepsi nelsoggetto splenectomizzato):
entro 1-3 ore dalla diagnosi (o dal sospetto diagnostico)
Nelle infezioni non gravi in cui non si ricerchi unadiagnosi eziologica
8/11/2019 Principi Tp Antibiotica 2014
9/291
1. Likely causative organism
Decide if community or healthcare-acquired infection Identify the most likely source of infection
Take appropriate specimens for microscopy, culture and
sensitivity testing. Imaging modalities may be necessary tolocate the source of infection.
Consider local epidemiological data Empiric antimicrobial choice depends on local susceptibility
patterns. Knowing the resistance profiles in thecommunity,hospital or unit helps in choosing antimicrobialsappropriately.
PRINCIPLES OF EMPIRICAL
ANTIMICROBIAL THERAPY
8/11/2019 Principi Tp Antibiotica 2014
10/291
1. Likely causative organism Decide if community or healthcare-acquired infection
Identify the most likely source of infection Take appropriate specimens for microscopy, culture and sensitivity testing. Imaging modalities may be necessary to locate
the source of infection. Consider local epidemiological data
Empiric antimicrobial choice depends on local susceptibilitypatterns. Knowing the resistance profiles in the community,hospitalor unit helps in choosing antimicrobials appropriately.
Presence of renal or hepatic dysfunction The risk-benefit of the antimicrobial must be determined on a case-
to-case basis. Maintenance doses are adjusted in line with theseverity of organ dysfunction. Others
Pregnancy, drug allergy
PRINCIPLES OF EMPIRICAL
ANTIMICROBIAL THERAPY
8/11/2019 Principi Tp Antibiotica 2014
11/291
3. Antimicrobial profile
Route of administration The intravenous route should always be used in severe
sepsis as oral absorption is unpredictable even in drugs withgood oral bioavailability.
Dose and interval Antibiotics can be categorised into three different classes
depending on the PK/PD indices associated with theiroptimal killing activity.
PRINCIPLES OF EMPIRICAL
ANTIMICROBIAL THERAPY
8/11/2019 Principi Tp Antibiotica 2014
12/291
8/11/2019 Principi Tp Antibiotica 2014
13/291
8/11/2019 Principi Tp Antibiotica 2014
14/291
8/11/2019 Principi Tp Antibiotica 2014
15/291
8/11/2019 Principi Tp Antibiotica 2014
16/291
8/11/2019 Principi Tp Antibiotica 2014
17/291
PRINCIPLES OF EMPIRICAL
ANTIMICROBIAL THERAPY
8/11/2019 Principi Tp Antibiotica 2014
18/291
8/11/2019 Principi Tp Antibiotica 2014
19/291
8/11/2019 Principi Tp Antibiotica 2014
20/291
8/11/2019 Principi Tp Antibiotica 2014
21/291
1928 1892
SirAlexander FLEMING(Lochfield 1881 1955 Londra)Premio Nobel per la Medicina nel 1945
Dott. Vincenzo TIBERIO(Sepino [CB] 1869 1915 Napoli)Ufficiale Medico della Regia Marina Militare Italiana
Lacqua del pozzo di casa Graniero, in Arzano, era abitualmente potabile, ma, allorquando si provvedeva alla ripulituradelle pareti con asportazione delle muffe verdeggianti, il bere quellacqua provocava negli utilizzatori enterocoliti. Alriformarsi delle muffe sulle pareti della cisterna lacqua diveniva nuovamente potabile Per ricercare per quanto tempo illiquido.avesse esercitato questo suo speciale potere iniettai le cavie sopravvissero tutte, eccetto quelle iniettate dopo10 giorni, che fecero notare un ritardo nella morte, rispetto ai controlli..Come tale questo liquido ha unazione preventivae terapica. Ho studiato il potere microbicida dei liquidi, ottenuti nel modo innanzi detto, per i bacteri patogeni pi
importanti Risulta chiaro da queste osservazioni che nella sostanza cellulare delle muffe esaminate sono contenuti deiprincipi solubili in acqua, forniti di azione bactericida bactericida..Per queste propriet le muffe sarebbero di forteostacolo alla vita ed alla propagazione dei bacteri patogeni.
8/11/2019 Principi Tp Antibiotica 2014
22/291
In the pre-antibiotic era, pneumonia was a dreaded killer of the young and a welcomed friend of the very old. Prior to the specifictherapies and antibiotics of the twentieth century many patients were better off if their disease ran its natural course. Thus doingnothing was often the best therapy. This photograph is common of many similar images of physicians, nurses and the family aboutthe bedside.
Waiting Out the Pneumonia Crisis,1895
8/11/2019 Principi Tp Antibiotica 2014
23/291
ScenarioIn March 1942, a 33-
year-old woman laydying of streptococcalsepsis in a New
Haven, Connecticut,hospital.
NEJM 2009
8/11/2019 Principi Tp Antibiotica 2014
24/291
Scenario
Despite the best efforts of contemporary medicalscience, her doctors could not eradicate herbloodstream infection.
Then they managed to obtain a small amount ofa newly discovered substance called penicillin,which they cautiously injected into her.
NEJM 2009
8/11/2019 Principi Tp Antibiotica 2014
25/291
ScenarioAfter repeated doses, her bloodstream was
cleared of streptococci, she made a full recovery,and she went on to live to the age of 90.
NEJM 2009
8/11/2019 Principi Tp Antibiotica 2014
26/291
8/11/2019 Principi Tp Antibiotica 2014
27/291
8/11/2019 Principi Tp Antibiotica 2014
28/291
S il d ffi i d ll h i t i ti i biS il d ffi i d ll h i t i ti i bi
8/11/2019 Principi Tp Antibiotica 2014
29/291
Sviluppo ed efficacia della chemioterapia antimicrobicaSviluppo ed efficacia della chemioterapia antimicrobica(1935(1935 1993)1993)
8/11/2019 Principi Tp Antibiotica 2014
30/291
Sixty-six years after her startling recovery, a
report described a 70-year-old man in SanFrancisco with endocarditis caused byvancomycin-resistant Enterococcus faecium
(VRE).
Scenario
NEJM 2009
8/11/2019 Principi Tp Antibiotica 2014
31/291
Despite the administration, for many days, of the
best antibiotics available for combating VRE,physicians were unable to sterilize the patientsblood.
Scenario
NEJM 2009
8/11/2019 Principi Tp Antibiotica 2014
32/291
He died still bacteremic.Scenario
NEJM 2009
8/11/2019 Principi Tp Antibiotica 2014
33/291
Clatworthy. Nature Biochem Biol 2007; 3: 541Clatworthy. Nature Biochem Biol 2007; 3: 541--88
8/11/2019 Principi Tp Antibiotica 2014
34/291
Meccanismi di resistenza Produzione di enzimi che
modificano o distruggonola molecola di antibiotico
Modificazione del sito dilegame dellantibiotico
Escrezione attiva dellamolecola (efflux pump)
Riduzione della
permeabilit dellamembrana
8/11/2019 Principi Tp Antibiotica 2014
35/291
Acquisizione della resistenza
8/11/2019 Principi Tp Antibiotica 2014
36/291
Selezione di batteri resistenti
8/11/2019 Principi Tp Antibiotica 2014
37/291
R i t i t i
8/11/2019 Principi Tp Antibiotica 2014
38/291
Resistenza intrinseca
8/11/2019 Principi Tp Antibiotica 2014
39/291
8/11/2019 Principi Tp Antibiotica 2014
40/291
Meccanismi di resistenza specifici
8/11/2019 Principi Tp Antibiotica 2014
41/291
Meccanismi di resistenza specifici
F tt i h f ilit l di
8/11/2019 Principi Tp Antibiotica 2014
42/291
Fattori che facilitano la comparsa di
resistenza Esposizione a livelli di antibiotico
subottimali Esposizione ad antibiotici ad ampio spettro Esposizione a microorganismi che
possiedono geni resistenti trasmissibili Mancata osservazione di regole
igieniche/protocolli di isolamento Uso indiscriminato nellindustria alimentare
e nellagricoltura
8/11/2019 Principi Tp Antibiotica 2014
43/291
Stime CDC
8/11/2019 Principi Tp Antibiotica 2014
44/291
Conseguenze Infezioni di difficile readicazione
Incremento della mortalit per infezione Comparsa di ceppi multi-resistenti (es:
MDR-TB)
Aumento dei costi Costi per singola dose:
Penicillina $0.24
Linezolid $86.90 (incremento costo di 360 volte)
R i IF WHEN
8/11/2019 Principi Tp Antibiotica 2014
45/291
Resistance: not IF... WHENMRSA/VRSA example
1940-1946 first-generation penicillins become widely available for treatmentof staphylococcus and streptococcus infections: strept throat pneumonia scarlet fever skin infections wound infections
By the 1950s, S. aureus acquired beta-lactamases (penicillinase) leading toresistance to first-generation penicillins. Methicillin (not recognized by
penicillinases) deployed to counter lactamase-producing strains By 1986, S. aureus with mutated PBP-2 prevalent: for treatment ofmethicillin-resistant S. aureus (MRSA), vancomycin became the front-lineantibiotic
1996 vancomyin-intermediate S. aureus (VISA) emerged
2002 vancomycin-resistant S. aureus (VRSA) identified late-1990s quinupristin/dalfopristin (Synercid) combination approved as anew option
2000 linezolid (Zyvox) approved as a new therapeutic 2003 first cases of resistance to linezolid reported
8/11/2019 Principi Tp Antibiotica 2014
46/291
MRSA
8/11/2019 Principi Tp Antibiotica 2014
47/291
End of antibioticsEnd of antibiotics -- the ultimate consequencethe ultimate consequence
8/11/2019 Principi Tp Antibiotica 2014
48/291
Terapia specifica Basata sullesito di un esame colturale
Solitamente si dispone anche di un test disensibilit in vitro
Con esito dellantibiogramma, scegliere ilfarmaco in base a:
profilo di tossicit / caratteristiche del pz spettro ristretto costi
8/11/2019 Principi Tp Antibiotica 2014
49/291
Le classi di antibiotici1. Interferenza con la sintesi della parete cellulare
Beta-Lattamici (penicilline, cefalosporine, carbapenemi,
monobattami) Glicopeptidi Polipeptidi Alcuni agenti antimicobatterici
2. Interferenza con la sintesi proteicaAzione su 30S ribosomiale Aminoglicosidi Tetracicline
Azione su 50S ribosomiale Cloramfenicolo Macrolidi Clindamicina Streptogramine
Oxazolidinoni
8/11/2019 Principi Tp Antibiotica 2014
50/291
3. Inibizione della sintesi degli acidi nucleiciAzione sulla replicazione del DNA Chinoloni / fluorochinoloni Metronidazolo
Azione sulla sintesi del RNA Rifampicina Rifabutina
4. Antimetaboliti
Sulfonamidi Dapsone Acido paraminosalicilico (PAS) Trimetoprim
5. Altri Daptomicina Polimixine
FARMACODINAMICAHow antibiotics kill bacteria: from targets to networks. 2010 Nature Reviews
8/11/2019 Principi Tp Antibiotica 2014
51/291
Microbiology 8, 423-435
8/11/2019 Principi Tp Antibiotica 2014
52/291
8/11/2019 Principi Tp Antibiotica 2014
53/291
8/11/2019 Principi Tp Antibiotica 2014
54/291
8/11/2019 Principi Tp Antibiotica 2014
55/291
Farmacocinetica di un
8/11/2019 Principi Tp Antibiotica 2014
56/291
Farmacocinetica di un
antibioticoDescrive i processi fondamentali dellorganismo
sul farmaco:AssorbimentoDistribuzioneMetabolismoEliminazione
Farmacodinamica di un
8/11/2019 Principi Tp Antibiotica 2014
57/291
Farmacodinamica di un
antibioticoDescrive leffetto fisiologico di una molecola sul
microorganismo allinterno del corpo, nonche ilsuo meccanismo di azione
Stretta relazione con la farmacocinetica
Concentrazione plasmatica di un antibiotico
8/11/2019 Principi Tp Antibiotica 2014
58/291
Concentrazione plasmatica di un antibiotico
dopo una singola somministrazione
LA PRIMA SOMMINISTRAZIONE DI QUALSIASI ANTIBIOTICO INQUALSIASI PAZIENTE E SEMPRE A DOSE PIENA!
Plasmatic concentration of an antibiotic after
8/11/2019 Principi Tp Antibiotica 2014
59/291
Plasmatic concentration of an antibiotic after
a single iv dose
Conc
entration
Concentrazione plasmatica di un antibiotico
8/11/2019 Principi Tp Antibiotica 2014
60/291
Co ce t a o e p as at ca d u a t b ot co
dopo una singola somministrazione
Pharmacokinetic parameters
8/11/2019 Principi Tp Antibiotica 2014
61/291
MIC: minimum inhibitory concentration
AUC: area under the curve
Cmax: maximum concentration (tissuespecific)
Pharmacokinetic parameters
Pharmacokinetic parameters
8/11/2019 Principi Tp Antibiotica 2014
62/291
Pharmacokinetic parameters
CONCETR
ATION
(mg/d
L)
TIME (hour)
MIC
Antibiotic Pharmacokinetics
8/11/2019 Principi Tp Antibiotica 2014
63/291
Antibiotic Pharmacokinetics
CONCETR
ATION
(mg/d
L)
TIME (hour)
AUC
Cmax
Antibiotic Pharmacokinetics
8/11/2019 Principi Tp Antibiotica 2014
64/291
ANTIMICROBIAL KILLING IS DEPENDENT ON BOTH THECONCENTRATION OF DRUG IN RELATION TO THE MIC AND
THE TIME THAT THIS EXPOSURE IS MAINTAINED
When the effect of concentration predominates over that of time, theantimicrobial is said to be CONCENTRATIONDEPENDENT andbactericidal effects are associated with an optimal free drug maximumconcentration to MIC ratio
(ffCmax/MICCmax/MIC).
When the effect of time is greater, the antibiotic displays TIME
DEPENDENT antibiotic activity, and bacterial outcomes are associatedwith free drug concentrations above the MIC for a defined portion of thedosing interval, or time above the MIC
(fT>MICfT>MIC)
Antibiotic Pharmacokinetics
Pharmacokinetic composite
8/11/2019 Principi Tp Antibiotica 2014
65/291
AUC > MIC
Cmax/MIC
Time > MIC
parameters
Pharmacokinetic composite
8/11/2019 Principi Tp Antibiotica 2014
66/291
parameters
CONCETR
ATION
(mg/d
L)
TIME (hour)
MIC
Time>MIC
E.G.: blactams, vancomycin, some macrolides, tigecycline, clindamycin
Pharmacokinetic composite
8/11/2019 Principi Tp Antibiotica 2014
67/291
parameters
CONCETR
ATION
(mg/d
L)
TIME (hour)
MIC
Cmax/MIC
E.G.: aminoglycosides, daptomycin, metronidazole, colistin, (fluoroquinolones)
8/11/2019 Principi Tp Antibiotica 2014
68/291
Pharmacokinetic composite
8/11/2019 Principi Tp Antibiotica 2014
69/291
parameters
CONCETR
ATION
(mg/d
L)
TIME (hour)
MIC
AUC>MIC
E.G.: fluoroquinolones
8/11/2019 Principi Tp Antibiotica 2014
70/291
Pharmacodynamics and pharmacokineticsPharmacodynamics and pharmacokinetics
8/11/2019 Principi Tp Antibiotica 2014
71/291
PENICILLINSPENICILLINSCEPHALOSPORINSCEPHALOSPORINS
CARBAPENEMSCARBAPENEMS
GLYCOPEPTIDESGLYCOPEPTIDESERYTHROMYCINERYTHROMYCIN
TIMETIME--dependentdependent killing +killing +short or no PAEshort or no PAEPDPDPKPK correlationcorrelation: T> MIC: T> MIC
TIMETIME--dependentdependent killing +killing +
prolonged PAEprolonged PAEPDPDPKPK correlationcorrelation : T> MIC: T> MIC
ProlongProlong exposure time:exposure time:maintainmaintain serumserum levelslevels> MIC (short> MIC (short intervalsintervalsoror continuouscontinuous infusion)infusion)
ProlongProlong exposure time:exposure time:
serumserum levelslevels mightmight bebe< MIC (short< MIC (short intervals)intervals)
AMINOGLYCOSIDESAMINOGLYCOSIDES
FLUOROQUINOLONESFLUOROQUINOLONESCLARITHROMYCINCLARITHROMYCINAZITHROMYCINAZITHROMYCIN
CONCENTRATIONCONCENTRATION--
dependentdependent killing +killing +prolonged PAEprolonged PAE
PDPDPKPK correlationcorrelation::peak/MIC or AUC/MICpeak/MIC or AUC/MIC
Achieve highAchieve high serumserum andand
tissuetissue concentrationsconcentrations(high(high doses, longdoses, longintervals)intervals)
Antibiotic Pharmacodynamics Dosing regAntibiotic Pharmacodynamics Dosing regimenimen
y py p
Ccorrelation and clinical significanceCcorrelation and clinical significance
8/11/2019 Principi Tp Antibiotica 2014
72/291
Parametri farmacocinetici
8/11/2019 Principi Tp Antibiotica 2014
73/291
Parametri farmacocinetici
Key message:
8/11/2019 Principi Tp Antibiotica 2014
74/291
Post-antibiotic effect Persistence of effect (inhibition of growth
or killing) after drug removed (or levelbelow MIC)
PAE + pharmacokinetics affects dosingstrategy
Post-antibiotic effect (PAE)
8/11/2019 Principi Tp Antibiotica 2014
75/291
Post antibiotic effect (PAE)
Nutrient broth
*
*Bacteria
* A
* AAntibiotics
Post-antibiotic effect (PAE)
8/11/2019 Principi Tp Antibiotica 2014
76/291
ost a t b ot c e ect ( )
Centrifuge Decant
*
*Resuspend
A A
* * * *
Post-antibiotic effect (PAE)
8/11/2019 Principi Tp Antibiotica 2014
77/291
( )
Exposed
*
*
*
*No growth
****
****
*
*Unexposed Grows
PAE (hours) = T - C T = is the time required for the count of cfu to increase 1 log10 (10-fold) above the count immediately
seen after drug treatment C = is the time required for the count to increase 1 log10 in an untreated control culture
PAE measures the time to reach normal logarithmic growth
Post-antibiotic effect (PAE)
8/11/2019 Principi Tp Antibiotica 2014
78/291
( )
1
10
100
1000
10000
0 1 2 3 4 5 6
Time (hours)
Removal ofAntibioticRemoval ofAntibiotic
ViableCo
unt(cfu/ml)
Control
1.6 hours to increase 1 log10
1 log10 increase
3.1 hours to increase 1 log10
AntibioticInduced death
PAE = 3.1 - 1.6 = 1.5 hoursDue to antibiotic effect onlyPAE = 3.1 - 1.6 = 1.5 hoursDue to antibiotic effect only
Persistent effect
8/11/2019 Principi Tp Antibiotica 2014
79/291
Bacterial killing/persistent effect
Drugs Therapy Goal PK/PDmeasurement
Concentrationdependent /prolongedpersistent effect
Aminoglycosides;daptomycin;ketolides;quinolones; metro
High peak serumconcentration
Cmax/MIC(24-hr AUC/MICfor quinolones)
Time dependent /no persistenteffect
Beta-lactams andmonobactams
Long duration ofexposure
Time above MIC
Time dependent /moderate to longpersistent effect
Clindamycin;macrolides;linezolid;tetracyclines;vancomycin;dalfopristin-
quinpristin
Enhanced amountof drug
24-hr AUC/MIC
8/11/2019 Principi Tp Antibiotica 2014
80/291
Correlazioni PK/PD: beta-lattamici
Exp. Opin. Pharmacother. 2000;1: 1203-1217
Optimizing Antimicrobials in the ICU:Continuous/Prolonged Infusions of Beta Lactams
8/11/2019 Principi Tp Antibiotica 2014
81/291
g
Cefotaxime vs Klebsiella in mouse lung model
Farmacodinamica degli
8/11/2019 Principi Tp Antibiotica 2014
82/291
aminoglicosidi in vivo
Moore et al, J Infect Dis 155: 93, 1987
Modelli di attivit battericida
8/11/2019 Principi Tp Antibiotica 2014
83/291
Curve di time-killing per P. aeruginosa
W.A. Craig et al., 1991, modified
0 2 4 6 80
2
4
6
8
10
0 2 4 6 80
2
4
6
8
10
0 2 4 6 80
2
4
6
8
10
64xMIC
16xMIC
4xMIC
MIC
1/4xMICControl
Tobramicina Ciprofloxacina Ticarcillina
CONCENTRAZIONE-DIPENDENTE TEMPO-DIPENDENTE
Tempo(hr)
Once-daily vs. Conventional Three-times
8/11/2019 Principi Tp Antibiotica 2014
84/291
Daily AminoglycosideRegimens
NicolauDP et al. AntimicrobAgents Chemother. 1995;39:650655
Vancomycin Outcome vs 24h-
8/11/2019 Principi Tp Antibiotica 2014
85/291
AUC/MIC ratio
24h-AUC/MICratio
Satisfactory Unsatisfactory
< 125 4 (50%) 4
> 125 71 (97%) 2
Hyatt et al, Clin Pharmacokinet 28: 143, 1995
8/11/2019 Principi Tp Antibiotica 2014
86/291
Factors which can influence
8/11/2019 Principi Tp Antibiotica 2014
87/291
therapeutic outcomeBacterial HumanInhibitory activity
absorptionSubinhibitory activity distributionConcentration-dependent
activity
metabolism
Time-dependent activity excretionBactericidal/bacteriostatic
activityprotein-binding
Post-antibiotic effect
Resistance
Oral Absorption of AntibioticsOral Absorption of Antibiotics
GoodGood:: sulfonamides
8/11/2019 Principi Tp Antibiotica 2014
88/291
chloramphenicol
clindamycin
trimethoprim
isoniazid, pyrazinamide
quinolonesdoxycycline
cycloserine
metronidazole
linezolid
Bad or variableBad or variable::
penicillins (some are, many arent)
cephalosporins (few are, most are not)
erythromycin (estolate conjugate)(clarithromycin is better)
UglyUgly:: aminoglycosides:
gentamicin
tobramycin
amikacin
netilmicinvancomycin
quinupristin/dalfopristin
meropenem
Therapeutic levels in theTherapeutic levels in the
b i l fl id?b i l fl id?
8/11/2019 Principi Tp Antibiotica 2014
89/291
cerebrospinal fluid?cerebrospinal fluid?GoodGood::ciprofloxacin
sulfonamides, trimethoprim
chloramphenicol
some 3rd generation cephalosporins
(e.g. ceftriaxone, ceftizoxime)
meropenem
cycloserine, metronidazole
pyrazinamide, isoniazidlinezolid
OKOK::(esp. when meninges inflamed)
ampicillin, ticarcillin
vancomycinrifampin
PoorPoor::
aminoglycosidesaminoglycosides
tetracyclinestetracyclinesclindamycinclindamycin
erythromycinerythromycin
cefaclorcefaclor
quinupristin/dalfopristinquinupristin/dalfopristin
(synercid)(synercid)
INTERRELATIONSHIP OF HYDROPHILICITY ANDLIPOPHILICTY OF ANTIBIOTICS ON THEIR
CO C C C S CS
8/11/2019 Principi Tp Antibiotica 2014
90/291
PHARMACOKINETIC CHARACTERISTICS
Condizioni parafisiologiche
8/11/2019 Principi Tp Antibiotica 2014
91/291
Sepsi
Condizioni parafisiologiche
8/11/2019 Principi Tp Antibiotica 2014
92/291
Ustionati
Condizioni parafisiologiche
8/11/2019 Principi Tp Antibiotica 2014
93/291
Obesi
General concept:
P i bi di
8/11/2019 Principi Tp Antibiotica 2014
94/291
Protein bindingx x x
x x xx x x
x x x
x x x
x x x
80%80%
Extensive protein binding
8/11/2019 Principi Tp Antibiotica 2014
95/291
Good: Allows slow, steady release of heavilybound drug, e.g. ceftriaxone
Bad: since less free drug available forbacteria, e.g. ceftriaxone
8/11/2019 Principi Tp Antibiotica 2014
96/291
Penicilline
8/11/2019 Principi Tp Antibiotica 2014
97/291
Derivate da Penicilliumchrysogenum.
PNC G e PNC V sonoprodotti non modificatidella fermentazione diPenicillium.
I derivati semisinteticisono creati aggiungendouna catena R alla
struttura base dellanellobetalattamico.
PENICILLINS
8/11/2019 Principi Tp Antibiotica 2014
98/291
bactericidal interferes with peptide cross-linking required to
produce stable cell walls development of resistance due to beta
lactamase production and changes in PBPs may accumulate in renal failure and cause
seizures
good tissue penetration (except prostate anduninflammed meninges)
Beta Lattamici
8/11/2019 Principi Tp Antibiotica 2014
99/291
B-lattamici inibiscono latranspeptidasi (PBP).
Effetto su batteri in rapida
crescita che sintetizzanoparete batterica /peptidoglicano
Le caratteristiche dello spettro
dazione dipendono: dalle dimensioni e dalla carica della molecola, dalla sua affinit per le PBPs, dalla resistenza di essa alle
beta-lattamasi. Azione: battericida
Struttura della parete cellulare
batterica
8/11/2019 Principi Tp Antibiotica 2014
100/291
A.Gram + B. Gram -
batterica
8/11/2019 Principi Tp Antibiotica 2014
101/291
8/11/2019 Principi Tp Antibiotica 2014
102/291
Penicilline Naturali
8/11/2019 Principi Tp Antibiotica 2014
103/291
Penicillina G (benzipenicillina) EV/IM Coniugaz con sali insolubili per preparazioni depot per ala via IM
PENICILLINA G PROCAINA PENICILLINA G BENZATINA
Penicillina V (fenossimetilpenicillina) OS
Attiva nei confronti di: Streptococchi,peptostr., B anthracis, Actinomyces,Corynebacterium, Listeria, Neisseria&Treponema.
PENICILLINE NATURALI
8/11/2019 Principi Tp Antibiotica 2014
104/291
Penicillin G Spectrum: mostly Gram+ Gram+ cocci
S. pyogenes: minimal resistance observed, does not produce beta-lactamases S. pneumoniae: modified PBP in 30-40% gave rise to PRSP (penicillin resistant S. pneumo), not duenot due
to betato beta--lactamaselactamase
most common cause of CAP (community-aquired pneumonia) 50-80% very common cause of otitis media ~35%
S. viridans: usually still sensitive Endocarditis (heart valve infection)
Enterococcus faecalis: PenG generally effective (not due to betanot due to beta--lactamase)lactamase) But note, E. faecium: highly resistant to PenG (92%) and vancomycin
Gram+ rods Clostridium tetani (tetanus), C. perfringens (gangrene, food poisoning) sensitive C. difficile resistant
Helical and spirochetes: Treponema pallidum (syphilis): sensitive to Pen G
Relatively little Gram- coverage (scarce penetration of outer membrane!) Use against sensitive Neisseria meningitidis: and PenG can penetrate meninges ONLY IF
ongoing inflammation
Neisseria gonorrhoeae however is now resistant due to beta-lactamases Enterobacteriaceae, Pseudomonas, H. influenzae: resistant
8/11/2019 Principi Tp Antibiotica 2014
105/291
8/11/2019 Principi Tp Antibiotica 2014
106/291
Will we ever find a cure for penicillin?
Clatworthy. Nature Biochem Biol 2007; 3: 541Clatworthy. Nature Biochem Biol 2007; 3: 541--88
THE ANTIBIOTIC TIMELINE
8/11/2019 Principi Tp Antibiotica 2014
107/291
Clatworthy. Nature Biochem Biol 2007; 3: 541C at o t y atu e oc e o 00 ; 3 5 88
8/11/2019 Principi Tp Antibiotica 2014
108/291
-lattamasi
8/11/2019 Principi Tp Antibiotica 2014
109/291
Insieme molto ampio ed eterogeneo di anzimi Spettro di azione molto ampio
-lattamasi AmpC
ESBLs Carbapenemasi
Ampiamente distriubite in GRAM-POS e GRAM-NEG
Rappresentano il principale meccanismo di resistenza per
STAFILOCOCCHI, GRAMSTAFILOCOCCHI, GRAM--NEG e ANAEROBINEG e ANAEROBI
-lattamasi
8/11/2019 Principi Tp Antibiotica 2014
110/291
Penicilline Anti-Stafilococciche Meticillina nafcillina oxacillina cloxacillina e
8/11/2019 Principi Tp Antibiotica 2014
111/291
Meticillina, nafcillina, oxacillina, cloxacillina edicloxacillina.
Resistenti alla degradazione ad opera dellepenicillinasi stafilococciche.
Mirate nei confronti di S. aureus, non efficaciverso gli streptococchi (Streptococco NONPRODUCE BETA-LATTAMASI!).
Meticillina non pi usata (tossicit). Oxacillina farmaco di scelta Breve emivita NOT FOR: MRSA, Methicillin-resistant
Staphylococcus epidermidis (MRSE) orENTEROCOCCI (Enterococchi NONPRODUCONO BETA-LATTAMASI!).
Attualmente in forte aumento ceppi MRSA!!
8/11/2019 Principi Tp Antibiotica 2014
112/291
Anti-staph penicillinase resistant
penicillins: clinical uses 1) Staphylococcal Infections
8/11/2019 Principi Tp Antibiotica 2014
113/291
penicillins: clinical uses 1) Staphylococcal Infections Spectrum similar to Pen G, but includes Staph. aureus & Staph.
epidermidis.
Community-acquired Methicillin-resistant forms of Staph aureus(MRSA) are increasing.
50-80% of S. epidermidis in hospitals is methicillin-resistant (butStaph. epi . is not a invasive or virulent).
Staphylococci cause skin infections (impetigo), abcesses in many
organs, pneumonias, prosthetic joint, catheter, and artificial valveinfections, endocarditis, meningitis (rare), bone infections(osteomyelitis: may require months of therapy).
2) Streptococcal infections, when Staph. is also a
possibility (although anti-staph penicillins are lesseffective than natura penicillins againsta streptococci)
Aminopenicilline
(penicilline a spettro esteso)
8/11/2019 Principi Tp Antibiotica 2014
114/291
(penicilline a spettro esteso) Ampicillina EV Amoxicillina (Velamox; OS).
Facile Spettro antimicrobico pi esteso. Gram negativi: E. coli, Proteus, Salmonella, Shigella,Haemophilus, M. catarrhalis, Klebsiella, Neisseria,Enterobacter, Bactoroides.
NOT FOR: MRSA, Methicillin-resistant Staphylococcusepidermidis(MRSE) or ENTEROCOCCI
DO NOT USE if beta-lactamase (penicillinase)producing Gram-neg strains
NB: Aminopenicillins should not be prescribed for patients suffering from tonsillitisuntil infectious mononucleosis has been excluded. Patients with mononucleosisreadily develop severe maculopapular exanthema even after a few tablets ofaminopenicillin. This effect is caused by production of heterophile antibodies and
should not be interpreted as true and lasting allergy
Aminopenicillins Aminopenicillins have spectra similar to natural penicillins with one exception: an
ddi i l i i h i id h i i h i id h li i d ll h
8/11/2019 Principi Tp Antibiotica 2014
115/291
additional aminogroup in their side chain increases their idrophylicity and allow themto pass through the porins in the outer memnbrane of some Gram-negative bacteria(E. Coli, P. mirabilis, S. Enterica, Shigella)
Even though they can penetrate the outer Gram-negative bacterial membrane, manyGram-neg bugs produce beta-lactamases that can degrade ampicillin.
For example: E. coli (80-90% of UTIs), 50% resistant to ampicillin due to beta-lactamase production Proteus mirabilis (UTIs), 30% resistant N. meningitidis generally sensitive, but some produce penicillinase N. gonorrhoeae significant penicillinase production now, resistant
H. influenzae ~30% produce beta-lactamases Most nosocomial pathogens are resistant either due to innate impermeability or
several resistance mechanisms including beta-lactamase production Sometimes used in combination with aminoglycoside for E. faecalis (synergy) Significant enterohepatic recycling : unmodified amp re-secreted into bile many
cycles, leading to high intestinal levels of the drug. Potentially useful for Shigella,
Salmonella, enteric infections. Greater risk of adverse effects such as diarrhea and C.difficile overgrowth.
8/11/2019 Principi Tp Antibiotica 2014
116/291
8/11/2019 Principi Tp Antibiotica 2014
117/291
-lattamasi
8/11/2019 Principi Tp Antibiotica 2014
118/291
Bush, Jacoby, Madeiros Classificationof -Lactamases
8/11/2019 Principi Tp Antibiotica 2014
119/291
Combinations with beta-
lactamase inhibitors Two combinations are available, both for oral and parenteral administration:i illi lb
8/11/2019 Principi Tp Antibiotica 2014
120/291
ampicillin + sulbactam amoxicillin + clavulanic acid The combinations are effective against many gram-negative and anaerobic bacteria
expressing beta-lactamase, and also against Staphylococcus aureus. Thus beta-lactamase inhibitors drmatically broaden the antimicrobial spectrum of theaminopenicillins
NB: These antibiotics are needless and should not be prescribed againststreptococci, enterococci or other bacteria that do not produce beta-lactamase.
Aminopenicillins with or without beta-lactamase inhibitor are widely used in clinical
practice. They are given in bacterial sinusitis, mesotitis and lower respiratory tractinfections, urinary and hepatobiliary tract infections, purulent gynecological infections,and other community-acquired infections.
Remember: 1) Bacteria have developed many beta-lactamases, and only some of them can be destroyed
with inhibitors. Many bacteria causing community acquired infection use to disposeplasmide-transmitted lactamases that can be inhibited with sulbactam, clavulanic acid or
tazobactam. However these inhibitors do not work against lactamases produced by majorityof nosocomial pathogens.
2) Beta-lactamase inhibitors possess weak, if any, natural antibacterial activity. From generalpoint of view, minimal clinically important difference exists between these three drugs.
Combinations with beta-
lactamase inhibitors Inclusion of beta-lactamase inhibitor increases
8/11/2019 Principi Tp Antibiotica 2014
121/291
c us o o beta acta ase b to c easescoverage of Gram- to also include:
M. catarrhalis (otitis media, pneumo, sinusitis) H. influenzae (otitis media, pneumo, sinusitis) S. pneumoniae (otitis media, pneumo, sinusitis) MSSA
Klebsiella Enterobacter E. coli N. gonorrhoeae
Good activity against anaerobes
8/11/2019 Principi Tp Antibiotica 2014
122/291
Aminopenicillins +beta-lactamase inhibitors:
clinical uses
8/11/2019 Principi Tp Antibiotica 2014
123/291
Otitis media, sinusitis, and respiratory tract infections(acute exacerbations of bronchitis or
chronic obstructive pulmonary disease (COPD) due to b-lactamase producing H. influenzae & Moraxellacatarrhalis.
High doses recently approved for otitis media due toStrep. pneumoniae Skin and Skin-structure infections caused by b-
lactamase-producing strains of Staph. aureus, E. coli,and Klebsiella sp.
UTIs due to b-lactamase-producing strains of E. coli,Enterobacter sp., and Klebsiella sp
BROAD-SPECTRUM (anti-
Pseudomonal) PENICILLINS karbenicillin, ticarcillin, azlocillin, mezlocillin, piperacillinP l id h i hi h ll t t ti i t G
8/11/2019 Principi Tp Antibiotica 2014
124/291
Polar side chain which allow even greater penetration into Gram-neg bacteria (increased ability to pass through the outer membraneporins)
More resistant to cleavage by Gram-neg beta-lactamases thanaminopenicillins
More active against Gram-neg bacilli, including many strains of P.Aeruginosa
Maintain Gram-pos activity of natural penicillins but (like naturalpenicillins) are susceptible to beta-lactamases of staphylococci Usually, the third generation cephalosporins are preferred to these
drugs because of lower costs.
USES OF BROAD-SPECTRUM(ANTIPSEUDOMONAL) PENICILLINS
1. Pseudomonas aeruginosa infections
8/11/2019 Principi Tp Antibiotica 2014
125/291
1. Pseudomonas aeruginosa infections(often with aminoglycosides)
2. Mixed infections - good gram negativeactivity, covers most B. fragilis
3. Complicated urinary tract infections &prostatitis - Carbenicillin indanyl OK orally.
4. Surgical prophylaxis - intra-abdominal,gynecologic surgery
ANTIPSEUDOMONAL PENICILLINS+ BETA LACTAMSE INHIBITORS
ticarcillin + clavulanic acid
8/11/2019 Principi Tp Antibiotica 2014
126/291
piperacillin + tazobactam The fullest antimicrobial potential of the penicillins has
been achieved by combining extended-spectrumpenicillins with beta-lactamase ihibitors
Calvulanate and tazobactam neutralize many beta-lactamases resulted in a marked enhancement of their
activity Highly active against: Gram- neg:
Pseudomonas, E. coli, klebsiella, enterobacter, serratia and
B. fragilis, H. Influenzae Gram-pos (NOT FOR MRSA) Nearly all anaerobic bacteria except for C. Difficile
8/11/2019 Principi Tp Antibiotica 2014
127/291
ANTIPSEUDOMONAL PENICILLINS+ BETA LACTAMSE INHIBITORS: Clinical uses
Extends spectrum towards b-lactamase-producing Enterobacteriaciae &Pseudomonas. For Pseudomonas infections, often combined with aminoglycosides.
8/11/2019 Principi Tp Antibiotica 2014
128/291
Indications are as follows: Septicemia due to b-lactamase-producing strains of Klebsiella sp., E. coli, Staph. aureus, &
Ps. aeruginosa
Lower respiratory tract infections due to b-lactamase-producing strains of Klebsiellapneumoniae, S. aureus, H. influenzae, & Moraxella catarrhalis
Bone & joint infections due to b-lactamase-producing Staph. aureus. UTIs (complicated & uncomplicated) due to b-lactamase-producing strains of E. coli,
Klebsiella, Ps aeruginosa, Citrobacter sp., Enterobacter sp., Serratia marcescens, & Staph. Gynecologic infections: endometritis due to b-lactamase-producing strains of Prevotella
(formerly Bacteroides) melaninogenica, Enterobacter sp., E. coli, Klebsiella pneumoniae, S.aureus, and Staph. epidermidis.
Treatment of mixed infections and for presumptive therapy prior to identification of thecausative organisms.
Appendicitis or peritonitis caused by b-lactamase-producing E. coli or Bacteroides fragilis Uncomplicated & complicated skin and skin structure infections caused by piperacillin-
resistant b-lactamase-producing Staph. Aureus
Post-partum endometritis or pelvic inflammatory disease caused by piperacillin-resistant b-lactamase-producing strains of E. coli Community-acquired pneumonia (moderate severity only) caused by piperacillin-resistant b-
lactamase-producing strains of H. influenzae & Ps. aeruginosa
Effetti collaterali delle penicilline
Farmaci molto sicuri con elevatoindice terapeutico
8/11/2019 Principi Tp Antibiotica 2014
129/291
indice terapeutico Reazioni da ipersensibilit: 5%
Rash reazione pi comune. Ampicillina: rash nel 50-100%
dai pz con mononucleosi. Orticaria, angioedema, schock
anafilattico (1/10000): evitaretutte le altre penicilline. Raramente crisi comiziali
accumulo in pz con insuffrenale
Infusione ev troppo rapida Soggetti predisposti
Clatworthy. Nature Biochem Biol 2007; 3: 541Clatworthy. Nature Biochem Biol 2007; 3: 541--88
THE ANTIBIOTIC TIMELINE
8/11/2019 Principi Tp Antibiotica 2014
130/291
Cefalosporine
Derivati B-lattamici semisintetici ottenuti
8/11/2019 Principi Tp Antibiotica 2014
131/291
aggiungendo diverse catene laterali allacido
aminocefalosporanico
pi resistenti alle beta-lattamasi rispetto apenicilline naturali.
Cefalosporine
8/11/2019 Principi Tp Antibiotica 2014
132/291
Ceftazidime
La catena laterale conferisceprotezione sterica dallazionedelle beta-lattamasi
Cefalosporine
Reazioni avverse
8/11/2019 Principi Tp Antibiotica 2014
133/291
5-10% cross-reattivit
negli allergici allepenicilline 1-2% reazione da
ipersensibilit neipazienti non allergicialle penicilline(soprattutto per I e II
generazione). Spettro dazione
ampio infezioniopportunistiche!
CEPHALOSPORINS Cephalosporin generations: generally get broader, more Gm- coverage
with later generationsG ti 1 G ll h d b tt G th G ti it tibl t
8/11/2019 Principi Tp Antibiotica 2014
134/291
Generation 1: Generally had better Gram+ than Gram- activity; susceptible tomany Gram- beta-lactamases
Examples: Cephalexin, Cefazolin Generation 2: Better resilience to Gram- beta-lactamases, Gram- coverage
(Cefotetan less active against Gram+) Examples: Cefuroxime
Generation 3: More potent, better Gram- beta-lactamase stability, betterpenetration; pick up some anti-Pseudomonal activity (Ceftazidime), give up someGram+ coverage (Ceftazidime: limited activitv against S. Aureus)
Examples: Cefpodoxime, Cefdinir, Cefixime, Cefotaxime, Ceftriaxone, Ceftazidime, Generation 4: Very broad spectrum (Gm- and Gm+)
Example: Cefepime Generation 5: MRSA and PRSP (penicillin-resistant Streptococcus pneumoniae)
coverage; Gm- activity similar to ceftriaxone (not for Pseudomonas!) Example: Ceftaroline
DO NOT USE IN: ENTEROCOCCI, LISTERIA MONOCYTOGENES,(MRSA, except 5th generation)
CefalosporineCefalosporine
Classificazione per generazioniClassificazione per generazioniGenerazioneGenerazione AttivitAttivit relativa su specierelativa su specie
8/11/2019 Principi Tp Antibiotica 2014
135/291
ppbatterichebatteriche
GramGram--positivepositive GramGram--negativenegative
PrimaPrima ++++++++ ++
SecondaSeconda ++++++ ++++
TerzaTerza ++ +++*+++*
QuartaQuarta ++++ ++++**++++**
* In parte attive anche su* In parte attive anche su P. aeruginosa;P. aeruginosa; ** molto attive su** molto attive su P. aeruginosaP. aeruginosa
Cefalosporine
8/11/2019 Principi Tp Antibiotica 2014
136/291
IIIa Generazione
Spettro: gram negativi > grampositivi
8/11/2019 Principi Tp Antibiotica 2014
137/291
positivi.
Ceftriaxone (Rocefin; IM/EV) Molto efficace sia contropneumococchi (penicillino-sensibili) che contro gram-neg
respiratori. Ottimo profilo farmacocinetico.
Ceftazidime (Glazidim) attivit
specifica contro Pseudomonas(ma ridotta verso Gram +!!).
CEPH: 1st Gen used predominantly against gram-positive cocci (streptococci and
staphylococci).Th i t f th i l d b t i i i d
8/11/2019 Principi Tp Antibiotica 2014
138/291
Their spectrum further includes corynabacteria, meningococci, andsome community-acquired stems of gram-negative rods likeEscherichia coli or Proteus mirabilis.
The drugs are active against anaerobes in the extent similar topenicillin. cefalotin, cefazolin (for parenteral administration) cefalexin, cefadroxil, cefaclor (for oral administration) (cefaclor has moderate effect against Haemophilus, so it belongs to
one-and-half generation) The drugs are predominantly used for treatment skin and soft tissue
infections, and for prophylaxis in surgical procedures (exceptcolorectal surgery and situations when methicillin-resistant
staphylococci are spread in the surgery department).
CEPH: 2nd Gen contain antibacterial activities of the 1st generation and extend to further
community-acquired gram-negative bacteria like Haemophilus influenzae,Moraxella catarrhalis, or less susceptible strains of E.coli or similarpatogens
8/11/2019 Principi Tp Antibiotica 2014
139/291
patogens. cefuroxime, cefamandol (for parenteral administration)
cefuroxim-axetil (for oral administration) prescribed for treatment respiratory tract infections (bacterial sinusitis or
mesotitis, pneumonia), and urinary and hepatobiliary tract infections. They can be used for prophylaxis in surgery as well. cefoxitin (only parenteral administration)
It is a representative of cefamycines. These antibiotics are closely related totrue cephalosporins differing in one substituent on cephem nucleus. Their common feature is a very good activity against relatively resistant anaerobe
Bacteroides fragilis. With its antibacterial activity against other gram-neg bacteria, cefoxitin has been
joined to the 2nd generation cephalosporins but shows limited activity against
Gram-pos cocci. Its typical disposal is intra-abdominal, pelvic, and gynecological infections, footinfections in diabetics, infected decubitus ulcers and other mixed aerobic-anaerobic infections. Unfortunately, resistance to cefoxitin raises quickly indepartments where this drug used to be given frequently.
CEPH: 3rd Gen can be divided in two subgroups according to their activity against Ps.aeruginosa: The subgroup A consists of antibiotics of similar spectrum as 2nd generation but with enhanced
activity against gram-negative bacteria and weaker effect against staphylococci.cefotaxim ceftriaxone (for parenteral administration)
8/11/2019 Principi Tp Antibiotica 2014
140/291
cefotaxim, ceftriaxone (for parenteral administration) These drugs are used for treatment of severe and life-threatening infections caused by community
gram-negative patogens like E.coli, H.influenzae, meningococci, salmonellae etc. The relevantclinical diagnoses are purulent meningitis, epiglotitis, sepsis of urinary or hepatobiliary tract originetc.
Ceftriaxone is an antibiotic of extreme long half-time (8 hrs) in addition that allows once-dailyadministration. This feature makes the treatment easier but is of particular importance in treatmentof outpatients or in home treatment. cefetamet-pivoxil, cefpodoxim-proxetil, cefixim, ceftibuten (for oral administration)
The position of these antibiotics is rather problematic. They can be used for treatment of mild ormoderate community acquired infections but cephalosporines of 2nd generation suffice in thesesituations usually. The only rational indication remains infection caused by pathogens ofmicrobiologically verified intermediate sensitivity where 2nd generation cephalosporins performonly a weak effect.
The subgroup B included antibiotics effective against Ps. aeruginosa and other problematic gram-negative pathogens. However, the stronger is the anti-pseudomonadal effect, the weaker is theactivity against staphylococci and other gram-positive microbes.
ceftazidime, cefoperazon (for parenteral administration) These antibiotics are used in nosocomial infections/sepsis caused by gram-negative bacteria.Ceftazidime is strongest anti-pseudomonal cephalosporin. Cefoperazons unique feature ispredominant excretion via the bile: this advocates for its usage in hepatobiliary tract infections andin renal insufficiency. Cefaperazon is available in a mixture with beta-lactamase inhibitor as well:cefoperazon/sulbactam that can be worthy against Acinetobacter sp. and some problematicpathogens owing beta-lactamase activity.
CEPH: 4th Gen
Antibiotics of this group have a broad spectrumsummarizing the 1st, 2nd and 3rd generation.
8/11/2019 Principi Tp Antibiotica 2014
141/291
They can resist some potent beta-lactamases.Nevertheless, their activity against staphylococci is notbetter than with cephalotin and activity againstPs.aeruginosa is not better than with 1Gen agents .
cefpirome, cefepime (only parenteral administration) used in nosocomial infections of special resistance
pattern (stable induction of ampC gene) or in nosocomialsepsis of unknown origin where covering the broad
spectrum of pathogens is necessary (i.e. febrileneutropenia).
8/11/2019 Principi Tp Antibiotica 2014
142/291
Ceftobiprole
8/11/2019 Principi Tp Antibiotica 2014
143/291
8/11/2019 Principi Tp Antibiotica 2014
144/291
8/11/2019 Principi Tp Antibiotica 2014
145/291
8/11/2019 Principi Tp Antibiotica 2014
146/291
8/11/2019 Principi Tp Antibiotica 2014
147/291
Carbapenemi Imipenem-Cilastina (Imipem EV), meropenem (Merrem EV) Cilastina: inibitore della deidropeptidasi previene la formazione
di un metabolita nefrotossico. Antibiotici betalattamici con spettro pi ampio
8/11/2019 Principi Tp Antibiotica 2014
148/291
Antibiotici betalattamici con spettro pi ampio. Staph(no MRSA), Strep (highly resistant), Neisseria, Haemophilus, Proteus,
Pseudomonas, Klebsiella, Bacteroides, anaerobes (escluso C. difficile) Nelle infezioni da Pseudomonasraccomandata associazione(AMINOGLICOSIDE, CHINOLONICO).
NO ACTIVITY AGAINST: MRSA, MRSE,Stenotrophomonas maltophilia, Pseudomonas cepacia
Tossicit:
Allergia crociata con penicillina: < 5 %. Imipenem epilettogeno
Imipenem Slightly more activity versus gram positive and a little less
activity with gram negative compared to meropenem Risk of seizures more common in renal failure
Meropenem Similar spectrum of activity as imipenem Little or no risk of seizures
Carbapenems Molecular properties:
Quite small molecules and have charge characterustics that allow them to utilizespecial porins in the outer membrane of Gm-neg bacteria
Structure resistant to cleavage by most beta-lactamases
8/11/2019 Principi Tp Antibiotica 2014
149/291
Structure resistant to cleavage by most beta-lactamases
Affinity for a broad range of PBPs from many different species of bacteria. very potent antibiotics of extremely broad spectrum including majority ofgram-positive and gram-negative patogenes and anaerobes.
The group of resistant bacteria microbes includes: methicillin-resistant staphylococci, Clostridium difficile,
Stenotrophomonas maltophilia, Pseudomonas cepacia Enterococcus faecium Some exceptionally resistant strains of Acinetobacter or Pseudomonas.
imipenem, meropenem (only parenteral administration)
These antibiotics are reserved for extreme resistant nosocomialinfections/sepsis.
8/11/2019 Principi Tp Antibiotica 2014
150/291
8/11/2019 Principi Tp Antibiotica 2014
151/291
Monobattamici
Aztreonam (Azactam; IM/EV;) Resistente alle beta-lattamasi.
8/11/2019 Principi Tp Antibiotica 2014
152/291
Spettro antibatterico ristretto. H. influenzae, N. gonorrhea(produttori di penicillinasi), E.coli, Klebsiella, Proteus,
Pseudomonas. Inattivo verso I Gram + e gliInattivo verso I Gram + e glianaerobi.anaerobi.
Non cross-reazione nei pz
allergici alle penicilline!
8/11/2019 Principi Tp Antibiotica 2014
153/291
Vancomicina
Glicopeptide triciclico Streptomycesorientalis.
8/11/2019 Principi Tp Antibiotica 2014
154/291
Inibisce la sintesi della parete battericalegandosi alle catene di peptidoglicanoin allungamento e prevenendo il cross-linking.
Attivo verso i Gram +, compresiMRSA, MDRSP, enterococchi, Staph.epidermidise clostridi.
Sinergico con AG. Azione: battericida
Vancomicina
8/11/2019 Principi Tp Antibiotica 2014
155/291
8/11/2019 Principi Tp Antibiotica 2014
156/291
Vancomicina
Resistenza: Ridotta permeabilit. Cambiamento negli aminoacidi del peptidoglicano
8/11/2019 Principi Tp Antibiotica 2014
157/291
(da ala-ala a ala-lattato). Enterococchi vanA Reazioni avverse Febbre e brivido, ipotensione, red man syndrome.
Somministrazione lenta!
Ototossicit. Nefrotossicit (exp se usata con AG) Eliminazione renale (90-100%). Emivita normale 6-10 h. Emivita fino > 200 h in pz con IR grave.
Possibilit di misurazione dei livelliplasmatici
Teicoplanin penetrates better in tissues except brain. very long half-time (33-70 hours) and can accumulate in organism. The first three doses should be given in 12-hour period for
saturation then the drug can be given once daily or in every-other-
8/11/2019 Principi Tp Antibiotica 2014
158/291
saturation, then the drug can be given once daily or in every-other-
day regime. well tolerated and can be administered in a rapid infusion, slow
intravenous injection, or intramuscular injection. adverse effects are much less frequent.
allergy (and also resistance) is only partially crossed betweenvancomycin and teicoplanin. the main limiting factor of teicoplanin prescription is its relatively high
cost. teicoplanin is usually administered when vancomycin treatment can
not be continued because of allergy, renal failure, impossibility offurther intravenous administration etc. Because of its long half-time, teicoplanin is useful for the outpatient
therapy.
Effetti collaterali dei glicopeptidiEffetti collaterali dei glicopeptidi
FrequenzaFrequenzaTipoTipo VancomicinaVancomicina TeicoplaninaTeicoplanina
TromboflebiteTromboflebite ++++++ ++++
8/11/2019 Principi Tp Antibiotica 2014
159/291
NefrotossicitNefrotossicit ++++++ --Rash cutaneoRash cutaneo ++++ ++++
NeutropeniaNeutropenia ++++ ++++
OtotossicitOtotossicit ++ --SindromeSindrome red manred man ++++++ --
Disturbi gastrointestinaliDisturbi gastrointestinali -- ++++
EpatotossicitEpatotossicit -- +++++++ = 5+++ = 5 -- 10%; ++ = 210%; ++ = 2 -- 4,9%; + = < 2;4,9%; + = < 2; -- = assente= assente
Vancomicina
8/11/2019 Principi Tp Antibiotica 2014
160/291
8/11/2019 Principi Tp Antibiotica 2014
161/291
Aminoglicosidi
8/11/2019 Principi Tp Antibiotica 2014
162/291
Aminoglicosidi Streptomycin
Isolated in 1943 by Selman Waksman from Streptomyces griseus Breakthrough drug for treatment of tuberculosis (Mycobacterium
tuberculosis)
8/11/2019 Principi Tp Antibiotica 2014
163/291
Gentamicin Isolated in 1963 from Micromonospora purpurea (mycin only if fromStrep.)
Significant use in treatment of Gram- infections includingPseudomonas
Kanamycin isolated in 1957 and was the Drug of choice until Gentamicin in 1963.
Amikacin Semi-synthetic, derived from Kanamycin
Designed to overcome resistance due to modifying enzymes
Aminoglicosidi Binds to 30s ribosomal subunit and:
Interferes with initiation, ribosome locked at AUG start codon of mRNA (at higherconcentrations)
Premature termination of translation Incorporation of incorrect amino acid leading to nonsense proteins.
8/11/2019 Principi Tp Antibiotica 2014
164/291
Highly positively charged Interacts with Gram- outer membrane and makes it leaky increased penetration of the drug. role in increasing penetration of other drugs. Scarce penetration into Gram+ envelope (do not bind Gram+ membrane)
Bactericidal unlike most protein synthesis inhibitors This is probably due to the activity against the membrane.
Access from periplasmic space to cytosol accomplished by energy-dependentactivebacterial ytransport mechanism requiring oxygen Non activity against anaerobic bacteria Work poorly un anaerobic and acidic environments (such as abscesses)
Widely used for for treatment of Gram+ infection ???
Combined with cell-wall inhibitor (synergy)
Cell-wall disruptors increase permeability ofaminoglycoside into Gram+ cell But beta-lactams and aminoglycosides in vitro at high concentrations can interact, undergo
chemical reaction, and inactivate each other Do not mix in the same solution This effect varies based on pairing of beta-lactam and aminoglycoside
Aminoglicosidi Spectrum and usage:
Gram- aerobes: Pseudomonas aeruginosa Tobramycin is more potent against Pseudomonas than gentamicin Acinetobacter spp. Enterobacteriaceae: Klebsiella, Proteus, Enterobacter, Serratia, Providencia... Haemophilus influenzae Etc.
8/11/2019 Principi Tp Antibiotica 2014
165/291
Gram+ aerobes: used in combination with a beta-lactam or vancomycin (synergy) Streptococcus Staphylococcus
Mycobacteria M. tuberculosis MAC
No activity against anaerobes anaerobes lack the ability to actively take up AG into their cytosol synergism is expressed against
BOTH some gram-positive (streptococci, enterococci) AND gram-negative (E.coli, Pseudomonas) bacteria Examples:
Often Pseudomonas (Gram-): high intrinsic resistance to mono-therapies Infective endocarditis (Gram+): Staph, Strep viridans, Enterococci
Aminoglicosidi Aminoglycosides are associated with significant nephrotoxicity or ototoxicity. Excreted primarily by glomerular filtration
serum half-life will be prolonged and significant accumulation will occur in patients with impaired renalfunction.
Toxicity may develop even with conventional doses, particularly in patients with prerenal azotemiaor impaired renal function.
Nephrotoxicity
8/11/2019 Principi Tp Antibiotica 2014
166/291
Usually reversible More common than ototoxicity, 5-20% of patients Aminoglycoside accumulates in proximal tubules of renal cortex, kills the cells Tubular cell degeneration can lead to sloughing of cells and fine sediment in urine
Ototoxicity Irreversible Less common than nephrotoxicity; toxicities do not appear to be correlated
Aminoglycoside accumulates in inner ear and leads to destruction of cochlear hair cells Produces reactive radicals that kill the hair cells Vestibular toxicity: imbalance, vertigo, tinnitus, nystagmus (involuntary eye movement)
More frequently seen with gentamicin Auditory toxicity: high frequency hearing loss
More common with amikacin, kanamycin (particularly damaging) Emergence unpredictable, could be after a single dose; can appear weeks after therapy is completed (continue monitoring) AG accumulate in inner ear fluids and are cleared slowly, hence latency
Possibly a genetic factor: mutation on ribosomal RNA in mitochondria that enables AG to bind to human ribosomes; leadingto disruption of mitochondrial protein synthesis
Neuromuscular blockage Rare Myasthenia gravis Drug induces auto-immune response that leads to blockage of neuromuscularcommunication Antibodies block acetylcholine receptors at neuromuscular junctions Fatigue, weakness
Aminoglicosidi
8/11/2019 Principi Tp Antibiotica 2014
167/291
PEAK LEVEL (see optimal values above) efficacy measured one hour after an infusion begins; TROUGH LEVEL (optimal:
8/11/2019 Principi Tp Antibiotica 2014
168/291
to respect a maximal treating period of2-3 weeks, than a pause should followof minimum 4-6 weeks
to prefer once-daily administration(except infective endocarditis wheremultiple daily doses are preferred)
while intravenous infusion, the time of
administration should be 30-45 minutes(the period more then 1 hour enhancesnephotoxicity, the period less then 20minutes enhances the risk ofneuromuscular blocade)
to monitor renal (CREATININE) andauditive functions three times weekly
to measure serum levels ofaminoglykosides (especially theTHROUG serum level)
*advanced age, persistently high trough serumlevels, duration of therapy, hypotension, concomitantliver disease, use of other nephrotoxins (e.g.vancomycin, furosemide)
Aminoglicosidi Gentamycin (IV/IM, opthalmic, topical)
The go-to aminoglycoside for Gram- aerobic infections Associated with ototoxicity, especially affecting vestibular system
Tobramycin (IV/IM, opthalmic, topical)
8/11/2019 Principi Tp Antibiotica 2014
169/291
Greater potency compared to Gentamycin against Pseudomonas Less ototoxicity than Gentamycin, but auditory loss possible Kanamycin (IV/IM, PO)
Can be used for intestinal infections or as sterilizing prophylaxis of the gut, oftencombined with cell-wall disruptor (beta-lactam, vanco)
Can be profoundly ototoxic, less impact on vestibular system
Amikacin (IV/IM) Less susceptible to enzymatic inactivation by resistance factors (side chain
modification made Amikacin more resistant to enzyme modification) Powerful agent, reserved for cases that are resistant to Gentamycin/Tobramycin,
so as not to foster resistance Somewhat less toxic to vestibular system than gentamycin If a bacteria is resistant to Amikacin, it is likely to be resistant to all the other
aminoglycosides as well Potency against P. Aeruginosa:
AMIKA > TOBRA > GENTA
Aminoglicosidi Reserved for serious infections onlyReserved for serious infections only
Elimination is renal (excreted unchanged by glomerular filtration): REQUIRE DOSE ADJUSTEMENT IN RENAL FAILURE!
Does not cross blood-brain barrier into CNS Aminoglycosides work excellent in blood, in extracellular fluid, and in urine. Their effect in the
inner area of inflammation may be poor due to limited penetrance and acidic condition. Due to serious toxicity concerns: ototoxicity, nephrotoxicity
8/11/2019 Principi Tp Antibiotica 2014
170/291
Concentrations require monitoring IV only for severe systemic infections; majority passed unmodified in urine If the patient is predisposed to renal dysfunction, important to monitor closely
Active against broad spectrum of Gram- aerobes and facultative anaerobes Weak coverage of Gram+ if used alone, but active if combined with another inhibitor of wall-
syntesis such as beta-lactams or glycopeptides. Poor coverage of obligate anaerobes
Aminoglycosides are preferably used in combination with other antibiotics. Typical indications for usage aminoglycosides include: a) severe infections or sepsis caused by gram-negative microbes and staphylococci:
Amonoglycosides are given especially at the onset of therapy, for rapid lowering of themassive bacterial load.
b) severe infections caused by semi-resistant microbes when monotherapy is notbactericidal: In these situations, synergistic effect of aminoglycosides and wall-affecting
antibiotics is often utilized. Examples: nosocomial infections caused by resistant gram-negative bacteria infective endocarditis caused by streptococci or enterococci infections in immunocompromised patients in whom bactericidal activity of antibiotics is
necessary.
8/11/2019 Principi Tp Antibiotica 2014
171/291
Aminoglicosidi Compared to other antibiotics, resistance to aminoglycosides is rare Primarily mediated by enzymatic modification of the OH and NH2
groups Phosphorylation Acetylation
8/11/2019 Principi Tp Antibiotica 2014
172/291
Adenylation Encoded on plasmids, transposons Amikacyn is the most resistant AG to enzyme modification
Pseudomonas Efflux pump removal of drug from cytosol Modified ribosomal binding site
Methylation of 16s ribosomal RNA Single mod can knock out streptomycin binding since it has a single
binding site; other AG have more than one, harder to evolve resistance
8/11/2019 Principi Tp Antibiotica 2014
173/291
8/11/2019 Principi Tp Antibiotica 2014
174/291
Tetracicline
8/11/2019 Principi Tp Antibiotica 2014
175/291
Tetracicline First tetracycline isolated 1945 from Streptomyces aureofaciens, chlortetracycline
(though apparently the Egyptians 1600 years ago may have benefitted fromtetracyclines in their beer and bread).
Tetracycline is derived from Streptomyces Minocycline and doxycycline are newer sintetic molecules (longer half-life, better oral
absorption)Ri b i i i i d h h ki i i b
8/11/2019 Principi Tp Antibiotica 2014
176/291
absorption) Ring substitutions to positions 5, 6, and 7 change pharmacokinetic properties, but notspectra complete cross resistance
Originally, their antimicrobial spectrum was broad: Gm+ and Gm-, plus many unusual pathogens. But significant resistance developing (except tigecycline new related molecule with
extremely broad spectrum) Dramatic overuse in animals Chelates, forms an insoluble complex with, calcium
Tooth discoloration of child if administered to pregnant mother, or to children < 8 y.o. Incorporates into bone, may affect bone growth in fetus
Possibly antagonistic with amino-penicillins; they diminish each others activities.
8/11/2019 Principi Tp Antibiotica 2014
177/291
8/11/2019 Principi Tp Antibiotica 2014
178/291
Bacteriostatic: shuts down protein synthesis, but doesnt lead to nonsense proteins(like aminoglycosides). As a result damage to cells is less severe BACTERIOSTATIC
TETRACYCLINES:SPECTRUM OF ACTIVITY
Mostly the same for all tetracyclines (except tigecycline) Aerobic Gram+:
S. pyogenes S. pneumoniae S. aureus: MSSA, CA-MRSA
Aerobic Gram-: many are becoming resistant N. gonorrheae (significant resistance)
8/11/2019 Principi Tp Antibiotica 2014
179/291
g (significant resistance) H. influenzae Enterobacteriacea: Klebsiella, Shigella, E. coli, Salmonella
Atypicals: Chlamydia trachomatis (STD) and Chlamydia (aka Chlamydophilia) pneumoniae (but
now azithromycin is preferred)
Rickettsia rickettsii: Rocky Mountain spotted fever Borellia burgdoferi: Lyme disease Pasturella multocida: from animal bites Mycoplasma pneumoniae: walking pneumonia Brucella spp. Vibrio cholerae
Bacillus anthracis: anthrax; 2 months treatment (spores) Treponema pallidum: syphilis (but Penicillin is the drug of choice) Plasmodia spp.: malaria prophylaxis Entamoeba histolytica
1) Respiratory, genitourinary or ocular infections caused by chlamydiae, mycoplasmata, andureaplasmata. These infections include walking pneumonia cause dy M Pneumoniae, COPD , acute and chronic urethritis
and/or urethral syndrome, epididymitis, cervicitis, some of pelvic inflammatory diseases, inclusionconjuctivitis and trachoma. (Alternative drugs are macrolides.)
2) Mild COPD exacerbation (some activity against: Gram+, H. Influenzae, Serratia) 3) Rickettsial infections: Q fever, ehrlichiosis, typhus fever etc. (Alternative drug is
TETRACYCLINES:CLINICAL USE
8/11/2019 Principi Tp Antibiotica 2014
180/291
3) Rickettsial infections: Q fever, ehrlichiosis, typhus fever etc. (Alternative drug ischloramphenicol)
4) Spirochetal infections: Lyme borreliosis, relapsing fever (Borrelia recurrentis), leptospirosis,syphilis and other treponemal infections. (Alternative drugs are penicillins, cephalosporines,macrolodes.)
5) Some other anthropozoonoses caused by non-pyogenic bacteria: brucellosis,campylobacteriosis, malleus, pasteurellosis, plague, rat-bite fever, or tularemia. (Alternative drugsare fluoroquinolones.)
6) Mild to moderate infections caused by anaerobes: acne, actinomycosis, some pelvicinflammatory diseases. (Alternative drugs are lincosamides and other antibiotics effective againstanaerobes.)
7) Mild specific skin infections (Acne) Remember: In majority of above-mentioned pathogens, no systematic monitoring of resistance
exists due to problems with cultivation. The percentage of resistance (and probability ofsuccessful treatment with various antibiotics) is not known.
DUE TO RELATIVELY FREQUENT RESISTANT ISOLATES (G+ and G-),THEY ARE NOT INDICATED FOR EMPIRIC TREATMENT OF SEVEREINFECTIONS
TETRACYCLINES:ADVERSE EFFECTS
Do not use outdated products due to higher chance of renal toxicity(tetracycline) Drug breaks down into antimicrobially inactive compounds that may
increase renal toxicity; use full course and do not store
Fanconi syndrome: numerous small molecule nutrients are notreabsorbed
8/11/2019 Principi Tp Antibiotica 2014
181/291
Fanconi syndrome: numerous small molecule nutrients are notreabsorbed Less of a problem with newer formulations (doxycycline,
minocycline) wich are genearrly safe even in renal failure Clearance is mostly hepatic/fecal
Accumulates in growing bone and teeth in fetuses and children.Permanently discolors the teeth and can affect bone growth. Not recommended for children < 12 y.o. or pregnant women
(Pregnancy category D) Chelates cations: avoid dairy, iron, antacid products for 2 hours
Esophagitis: drink a lot of water and remain upright for 30 minutes Photosensitivity
8/11/2019 Principi Tp Antibiotica 2014
182/291
MACROLIDES Originally, exhibited a broad-spectrum antibacterial activity involving gram-positive and gram-
negative bacteria, anaerobes, spirochetes, and obligatory intracellular pathogens (chlamydiae,mycoplasmata).
most important drug of that time was erythromycine, isolated 1952 from a soil microbeStreptomyces erythreus.
Its usage was limited because of frequent disagreeable side effects like diarrhea, nausea and
vomiting. In 80ties, modern macrolides were introduced widely. Later drugs (azithro-, clarithro-, telithro-)
8/11/2019 Principi Tp Antibiotica 2014
183/291
g, y g ( , , )have broader spectra, especially Gm-. better acid stability and oral bioavailability
They became very popular because of low frequency of side effects and comfortable usage. Frequent resistance has been developed mainly in gram-positive cocci (staphylococci,
streptococci, and pneumococci) and in gram-negative (enterobacteria, H.influenzae) as aconsequence of their massive prescription. The number of resistant isolates exceeds 50% in many countries and their further destiny become
problematic. Frequently used for community-acquired respiratory infections; also for skin, otitis media (ear) Alternative drug for Strep., Staph., H. flu infections for pen-allergic Excellent tissue penetration, especially azithromycin and clarithromycin, but not to CNS
Target the 50s large ribosomal subunit in bacteria, inhibit protein synthesis Similar MOA to clindamycin and chloramphenicol (shared binding site) Bacteriostatic, except at very high concentration can be bactericidal
Macrolides Excellent tissue penetration But low serum levels
Tissue:blood ratio 10-100:1 highly concentrated in tissue, especially in the lung and in tonsils Extremely high penetration into host cells (good for intracellular
parasites such as Chlamydia) penetrates poorly into CNS synovial fluid and fetal tissues
8/11/2019 Principi Tp Antibiotica 2014
184/291
pa as tes suc as C a yd a) penetrates poorly into CNS, synovial fluid and fetal tissues Oral bioavailability: variable
Erythromycin (not acid stable) ~25%, should be taken on emptystomach
Clarithromycin and azithromycin ~50% (not influeced by food) T Erythro: ~1.5-2h (administered x3 in die) Clarithro: ~3-7h (administered x2 in die) Azithro: 2-4 days (administered once in die, short courses: 5-7 days)
a 3-day administration can make therapeutical levels in tissues for 7-14 days transported to a locus of inflammation in leukocytes. Consequently, drug
concentration in the site of inflammation is high, whereas serumconcentration is extremely low.
Macrolides: spectrumand clinical use
Good Gm+ and reasonable Gm- activity Clarithromycin and azithromycin more potent than erythromycin for Gram-neg coverage
Staph. Aureus (some isolates), but not MRSA S. pneumoniae resistance is rapidly on the rise (telitro is active against clarithro and azitro- resistant isolates) S. pyogenes M. cattarhalis
N. menengitidis Mycoplasma (walking pneumonia)
8/11/2019 Principi Tp Antibiotica 2014
185/291
Chlamydia Not Enterobacteriacae, cannot penetrate outer cell membrane (except for Campylobacter and some Shigella) Not Pseudomonas H. influenzae (not erythromycin), Atypicals (not easily categorized by Gram stain technique) Mycoplasma pneumoniae (walking pneumonia) Legionella pneumophilia (Legionares disease) Helicobacter pylori Chlamydia trachomatis (STD) and Chlamydia (aka Chlamydophila) pneumoniae Mycobacterium avian complex (MAC): Clarithro- and azithro-
Uses: respiratory infections (bronchitis and mild community-acquired pneumonia), mainly in atypical pneumonia and in legionellosis. urogenital infections caused by chlamydiae, mycoplasmata, and ureaplasmata.
may be used for treatment tonsillitis or lyme borreliosis (erythema migrans) in patients with allergy to beta-lactam antibiotics. special indications include campylobacteriosis (travelers diarrhea), tularemia in children, mycobacteriosis (in association with otherantibiotics) etc.
NB: Except legionellosis, macrolides should not be used for treatment severe infections. Their prescriptionmust be correlated to the frequency of resistance in pathogenic microbes in every country or district.
Generally, macrolides are not appropriate for treatment staphylococcal infections as well.
Macrolides Clarithromycin 2-4x more potent than erythromycin
Broader spectrum of coverage compared to erythromycin, more Gram- Somewhat more potent against Gram+ than azithro Macrolide of choice for treatment of:
Mycobacterium avium complex (MAC); common opportunist in AIDS H. pylori
A ith i
8/11/2019 Principi Tp Antibiotica 2014
186/291
Azithromycin More potent than erythromycin; higher tissue conc (e.g. lungs) than clarithro- Better Gm- coverage than clarithromycin, but less Gm+ than clarithromycin Macrolide of choice for: Chlamydia trachomatis, M. catarrhalis, H. influenzae, N.
gonorrhea (if patient is beta-lactam allergic), Legionella Used for some tougher infections: COPD exacernations, pneumonia (CAP),Legionella, mild skin infections
Telithromycin Binds more tightly to bacterial ribosome, and in more than one site Bugs that are erythromycin resistant (and clarith-, azith- too) may be still
susceptible to telithromycin Does not induce expression of erm (erythromycin ribosome methylase) that
methylate parts of ribosomal RNA to reduce binding of other macrolides Similar spectrum to azithromycin, also covers Penicillin-resistant S. Pneumo (but
not MRSA)
Macrolides Resistance is on the rise for S. pneumo (and much more rarely, for
S. pyogenes) Often associated with resistance to penicillin (and clindamycin)
Common mechanisms:Methylation of ribosome binding site via erm (erythromycin ribosomal
8/11/2019 Principi Tp Antibiotica 2014
187/291
Methylation of ribosome binding site via erm (erythromycin ribosomalmethylation) enzymes
S pneumo Affects erythro-, clarithro-, azithro-, but NOT telithromycin
Erm expression is inducible Active macrolide efflux pumps mef gene (macrolide efflux) S pneumo, S aureus, S epidermidis
Rare: esterases cleave the lactone ring
Intrinsic Enterobacteriacea resistance due to outer membrane permeability
8/11/2019 Principi Tp Antibiotica 2014
188/291
http://www.ecdc.europa.eu/en/publications/Publications/antimicrohttp://www.ecdc.europa.eu/en/publications/Publications/antimicro bialbial--resistanceresistance--surveillancesurveillance--europeeurope--2012.pdf2012.pdf
8/11/2019 Principi Tp Antibiotica 2014
189/291
8/11/2019 Principi Tp Antibiotica 2014
190/291
8/11/2019 Principi Tp Antibiotica 2014
191/291
Resistenza dello pneumococco
8/11/2019 Principi Tp Antibiotica 2014
192/291
Macrolides: adverse effects Erythromycin
GI discomfort, diarrhea (13-32%) sometimes used as a prokinetic QT prolongation risk of ventricular arrhythmias. Careful with other drugs that can have QT prolongation Drug interactions:
P-glycoprotein inhibitor: e.g. interacts with digoxin CPY3A4 inhibitor: e.g. interacts with carbamazepine, cyclosporin CYP1A2 inhibitor: e.g. interacts with theophyline and caffeine
Clarithromycin Drug interactions. E g many anti-retroviral drugs interact (not to be used with HIV patients)
8/11/2019 Principi Tp Antibiotica 2014
193/291
E.g. many anti-retroviral drugs interact (not to be used with HIV patients) Colchicine
QT prolongation risk of ventricular arrhythmias. Careful with other drugs that can have QT prolongation Teratogenic effects observed in animal models (Pregnancy category C) Dizziness
Azithromycin Few drug interactions Do not take with antacids, impairs absorption Rare hepatotoxicity QT prolongation risk of ventricular arrhythmias. Careful with other drugs that can have QT prolongation Pregnancy category B
Telithromycin Potentially fatal liver toxicity found after it was on the market (FDA Boxed warning) Aggravates myasthenia gravis Due to potentially severe adverse effects, telithromycin not to be used for mild cases or to treat bronchitis,
sinusitis. Removed indications for those. NOW, only indicated use is CAP (and as an alternative option)
8/11/2019 Principi Tp Antibiotica 2014
194/291
8/11/2019 Principi Tp Antibiotica 2014
195/291
8/11/2019 Principi Tp Antibiotica 2014
196/291
SULFA DRUGSFolic Acid Pathway Inhibitors
8/11/2019 Principi Tp Antibiotica 2014
197/291
SULFA DRUGSFolic Acid Pathway Inhibitors
SULFONAMIDES, TRIMETHOPRIMSULFONAMIDES, TRIMETHOPRIM
selective toxicity:selective toxicity:
sulfonamides: animal cells do not make folate, wesulfonamides: animal cells do not make folate, weabsorb it from the environmentabsorb it from the environment
8/11/2019 Principi Tp Antibiotica 2014
198/291
trimethoprim: has much higher affinity for thetrimethoprim: has much higher affinity for thebacterial DHFR than the mammalian DHFRbacterial DHFR than the mammalian DHFR
(1:50.000(1:50.000100.000)100.000)
co-trimoxazole = trimethoprim + sulfamethoxazole TMP/SMX (ratio 1:5)
TMP-SMX
SMX is a PABA analog thatbinds to dihydropteroatesynthase (synthatase) andprevents it from using PABA
TMP binds to and inhibitsdihydrofolate reductase
8/11/2019 Principi Tp Antibiotica 2014
199/291
Depleting folic acid hinders theeventual production of DNA sobacteria are unable toreproduce
SMX given with TMP synergistic effect Alone, each is bacteriostatic,
together bactericidal
85% bioavailable, not affected by food Broad distribution in tissues (penetrate
excellently into tissues and cells).
TMP is more lipophilic, so it gets concentrated tohigher levels in tissue than SMX, so 1:5
8/11/2019 Principi Tp Antibiotica 2014
200/291
higher levels in tissue than SMX, so 1:5(SMX:TMP) ends up ~1:20, which is optimal forsynergy
Both penetrate to CSF and across and placentalbarrier
SMX gets acetylated in the liver, TMP is
excreted in urine unchanged
Synergistic combinations ofTrimethoprim & Sulfamethoxazole
(Bactrim) Staph sensitivity Sulfamethoxazole MIC = 3 ug/ml Trimethoprim MIC = 1 ug/ml combo MIC = 0.3 Sulf & 0.015 Trim
8/11/2019 Principi Tp Antibiotica 2014
201/291
20:1 ratio most effective20:1 ratio most effective
Advantages more likely to be cidal broader spectrum decreased resistance lower doses = lower toxicity
8/11/2019 Principi Tp Antibiotica 2014
202/291
TMP-SMX: clinical uses
severe diarrheal diseases with fever (especially ifsalmonella is expected to be the cause) urinary tract infections (if local E. Coli resistant rates
8/11/2019 Principi Tp Antibiotica 2014
203/291
However, co trimoxazol is rather a drug of second choice formost of these infections because safer and/or more effectivealternatives do exist.
Special indications include therapy or prophylaxis in HIV/AIDS patients (pneumocystosis,
toxoplasmosis) Nocardiosis
Brucellosis long-term treatment of staphylococcal osteomyelitis etc.
TMP-SMX adverse reactions
Crystallurea Metabolized sulfonamides are insoluble and form crystals in urea Maintain hydration
Sulfonamides compete for bilirubin-binding sites on plasma albumin andmay increase blood levels of unconjugated bilirubin Kernicterus (can notbe given to pregnant women or to newborns and sucklings up to the age of
2 months) In G6PD-deficient patients, risk of hemolytic anemia Clearance is throug hepatic acetylation Slow acetylators have a higher
8/11/2019 Principi Tp Antibiotica 2014
204/291
Clearance is throug hepatic acetylation Slow acetylators have a higherrisk of developing toxicity
Many drug-interactions, for example: warfarin, cyclosporin, rifampin,
dapsone, phenytoin, etc Hypersensitivity allergic reaction (6-8%): Rash Urticaria Erythema multiforme Steven-Johnson Syndrome Toxic epidermal necrolysis
HIV-patients show more frequent and more severe hypersensivity reactions(25-50%)
8/11/2019 Principi Tp Antibiotica 2014
205/291
8/11/2019 Principi Tp Antibiotica 2014
206/291
Fluorochinoloni
Ciprofloxacina (Ciproxin; OS/EV) Levofloxacina (Tavanic; OS/EV) Moxifloxacina (Avalox; OS).
Derivati sintetici dellacido nalidixico
8/11/2019 Principi Tp Antibiotica 2014
207/291
Derivati sintetici dell acido nalidixico.
Azione: battericida. Agiscono sia su microorganismi in fase di
crescita che in fase stazionaria
Alta concentrazione nelle urine e ottimapenetrazione nei tessuti
8/11/2019 Principi Tp Antibiotica 2014
208/291
Inibiscono le DNA girasi etopoisomerasi IV: blocco del processodi duplicazione e trascrizione del DNA
Resistenza ai fluoroquinoloni
Mutazione della DNA Girasi (comune) Efflux-pump
Riduzione del numero di porine ridottoingresso intracellulare.
8/11/2019 Principi Tp Antibiotica 2014
209/291
8/11/2019 Principi Tp Antibiotica 2014
210/291
Spettro antibiotico
Efficace vs. gram +, gram (incl Pseudomonas), atipici.
Fluorochinoloni respiratori (levofloxacina e moxifloxacina). Attivi verso Strep(incluse forme penicillino resistenti), S.
aureus(not MRSA), H. influ, M. cat(including penicillin-resistant strains), e atipici. Utilizzati in AOM, sinusite, faringite
8/11/2019 Principi Tp Antibiotica 2014
211/291
a , s s , a g
Fluorochinoloni antipseudomonas (ciprofloxacin/ofloxacin)
Attivi contro Pseudomonas, H. flu, M. cat. Strep pyogenes, Strep pneumoniae, eMRSA sono resistenti. In profilassi nei pz con fibrosi cistica. Formulazione topica.
Levofloxacina e Moxifloxacina hanno attivit anche
verso ceppi di Staphcipro-resistenti. Ottimi farmaci anti TB (oflo, levo, moxi)
Fluorochinoloni
Ciprofloxacin Osteomyelitis, peritonitis, pneumonia, sepsis, UTI,
infectious diarrhea, gonorrhea, otitis, soft tissue
infections (good penetration into lungs, tissue, bone,and peritoneum) Active against gram negative organisms no anaerobe
8/11/2019 Principi Tp Antibiotica 2014
212/291
Active against gram negative organisms, no anaerobecoverage, little to no strep coverage
Pseudomonas activity notable (better than other FQ) Levofloxacin
Better gram positive activity including staph, strep and
Enterococcus faecalis
8/11/2019 Principi Tp Antibiotica 2014
213/291
Fluorochinoloni
Effetti collaterali. Cefalea, nausea/vomito, vertigini. Tendinopatie e rotture tendinee, artralgie. Abbassano la soglia epilettogena (CIPRO>LEVO) Ipoglicemia (gatifloxacina ritirata dal mercato) Allungamento QT
8/11/2019 Principi Tp Antibiotica 2014
214/291
(Sparfloxacin, Grepafloxacin) > Moxifloxacin, Levofloxacin >Ciprofloxacin
Riacutizzazione di miastenia gravis Da evitare nei bambini (possibile accumulo nelle
cartilagini in accrescimento)
Ottimo assorbimento enterico, ma non assumere concationi.
Linezolid
Unico rappresentante della classe oxazolinidoni Meccanismo di azione: legame con la subunita
23S del ribosoma batterico batteriostatico Zyvoxid (OS/EV) 300mg die fino a 600mg BID
Otti bi t OS (bi di ibilit
8/11/2019 Principi Tp Antibiotica 2014
215/291
Ottimo assorbimento per OS (biodisponibilita
circa 100%). Spettro dazione: batteri G+ inclusi MRSA,
VISA, VRSA, VRE. Mycobacterium
tuberculosis Non attivo contro batteri G-!
Linezolid
Precauzioni: uso concomitante di MAOi, SSRIs,amitriptilina
Effetti collaterali: Neuropatia ottica Mielosoppressione
8/11/2019 Principi Tp Antibiotica 2014
216/291
Mielosoppressione Acidosi lattica Neuropatia periferica
Ottima diffusione nei tessuti
8/11/2019 Principi Tp Antibiotica 2014
217/291
8/11/2019 Principi Tp Antibiotica 2014
218/291
Metronidazole
Bactericidal, cytotoxic to obligate anaerobes and somefacultative anaerobes
Concentration-dependent killing Diffuses across bacterial membranes Essentially 100% bioavailable after oral administration Reaches very high serum concentrations
E ll t ti t ti
8/11/2019 Principi Tp Antibiotica 2014
219/291
Excellent tissue penetration
Penetrates blood-brain barrier to CSF (~45%/100% for -/+ meningitis) Good penetration into brain abscesses Metabolized in the liver
If there is liver impairment, serum
Top Related